Navigation Links
BioMarin Announces Fourth Quarter and Full Year 2010 Financial Results
Date:2/17/2011

tax expense

(1)0.61.1(222.0)(7.0)(227.3) 15 Depreciation3.43.74.24.415.7 24 Amortization0.10.91.01.03.0 4 EBITDA (Loss)6.56.82.5(12.4)3.4 (11) - 1 Stock-based compensation8.59.210.09.837.5 43 Gain on sale of equity investments(0.9)---(0.9) — Contingent consideration

(2)0.70.83.1(0.6)4.0 11 Material non-recurringConvertible debt exchange

(3)---13.713.7 — Acquisition expenses

(4)--1.8-1.8 — Adjusted EBITDA$
4.8$   16.8$
7.4$
.5$
59.5 $43 - $55 (1)  Includes the release of the Company's income tax valuation allowance during 2010.(2)  Represents the changes in the fair value of contingent acquisition consideration payable for the period.   (3)   Represents debt conversion expense associated with the early conversion of a portion our convertible debt in November 2010.(4)   Represents transactions costs associated with the acquisition of ZyStor Therapeutics Inc., during the third quarter of 2010.   Reconciliation of GAAP Net Income (Loss) to EBITDA and Adjusted EBITDAFor the Four Quarters and Fiscal Year 2009(in millions)(unaudited) 2009Three Months EndedYear Ended DecemberNOTESMarch 31June 30September 30December 3131, 2009GAAP Net Income/(Loss)$
(13.1)$
.3$
.6$
4.7$
(0.5)Interest expense, net1.93.51.91.79.0Income tax expense0.40.50.9(0.8)1.0Depreciation2.83.22.43.111.5Amortization1.21.90.20.23.5EBITDA (Loss)(6.8)10.412.08.924.5Stock-based compensation7.89.08.98.834.5Gain on sale of equity investments-(1.6)--(1.6)Material non-recurringUpfront license fees

(1)8.8---8.8Impairment charges

(2)5.9---5.9Adjusted EBITDA$
5.7$   17.8$
20.9$
7.7$
72.1(1)  Represents upfront license payments related to our collaboration agreement with La Jolla Pharmaceutical Company in the first quarter of 2009.   (2)  Includes impairment losses on investments in Summit plc. and La Jolla Pharmaceutical Company recognized during the first quarter
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. BioMarin Initiates Pivotal Phase 3 Trial for GALNS for the Treatment of MPS IVA
2. BioMarin to Host Fourth Quarter and Full Year 2010 Financial Results
3. BioMarin Initiates Phase 1/2 Trial for BMN 701 for the Treatment of Pompe Disease
4. BioMarin Initiates Phase 1/2 Trial for BMN 673 for the Treatment of Genetically-Defined Cancers
5. BioMarin to Present at the J.P. Morgan 29th Annual Healthcare Conference
6. BioMarin to Present at the Deutsche Bank 2010 BioFEST Conference
7. BioMarin Completes Partial Exchange of Convertible Notes Due 2013 for Common Stock
8. BioMarin Announces Third Quarter 2010 Financial Results
9. BioMarin to Host a Research and Development Day on October 19th
10. BioMarin Appoints William Young and Kenneth Bate to Its Board of Directors
11. BioMarin to Present at the UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... -- ChinaMarketResearchReports.com adds "China Orthopedic Instrument Industry Report, 2013-2015" ... (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ) Benefiting from aging ... China,s orthopedic instrument industry has seen rapid ... from 3.28 billion yuan in 2006 to 9.85 billion ...
(Date:1/15/2014)... Texas , Jan. 15, 2014  Novation, the leading ... awarded several new IT value-added reseller (VAR) national contracts ... IT goods and services at lower costs. These include ... services such as initiative assistance and ongoing IT consulting ...
(Date:1/15/2014)... BreedIT Corp (OTC: BRDT), through its Israeli ... sophisticated agro-breeding solutions for plant breeders and researchers, today ... of directors appointed chemistry and pharmaceutical industry expert Dr. ... the board. From 1975 to 2012, Dr. ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
(Date:7/9/2014)... 8, 2014) Researchers from Montefiore Medical Center ... of Yeshiva University will present new findings at ... 12 July 17 in Copenhagen, Denmark. Data from ... prompt transition from cognitive normality to mild cognitive impairment ... Einstein Aging Study , established in 1980 to examine ...
(Date:7/9/2014)... watching World Cup highlights, Brian Williams refreshing old school ... positions on railings. A University of Colorado Cancer Center ... shows that YouTube also allows researchers, journals, and health ... of skin cancer and prevention. , "No matter what ... how we communicate around the world," says Chante Karimkhani, ...
(Date:7/9/2014)... National Institute of Allergy and Infectious Diseases (NIAID), ... launched an early-stage clinical trial of CRS3123, an ... difficile ( C. difficile ) infection. CRS3123 ... that inhibits C. difficile growth while sparing normal ... enroll up to 30 healthy men and women ...
(Date:7/9/2014)... A retrospective study conducted by researchers at Tufts University ... adults with intellectual and developmental disabilities, the likelihood of ... dental care increased. The findings, published in the July/August ... help improve interventions designed to address the oral health ... reviewed the dental records of 107 patients at one ...
(Date:7/9/2014)... older age with kidney and heart disease have raised ... older adults. However, in the first study to look ... of Medicine at the University of Pennsylvania report that ... life expectancy and cardiovascular health as very healthy older ... of the ever increasing organ transplant waitlists, the authors ...
Breaking Medicine News(10 mins):Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 3Health News:Study of dermatology on YouTube shows new ways science reaches public 2Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2Health News:Adults with special needs see gains, challenges with long term oral care 2Health News:Adults with special needs see gains, challenges with long term oral care 3Health News:Penn study finds living kidney donation does not increase risk of death or heart disease for older 2
... natural resource restoration planning process following the BP Deepwater Horizon ... of the Interior (DOI) today announced plans to develop a ... as part of the ongoing Natural Resource Damage Assessment (NRDA). ... scoping meetings in each of the affected Gulf Coast states. ...
... anterior cruciate ligament (ACL) knee reconstruction with a hamstring tendon ... to suffer from pain and mobility issues15 years after surgery, ... Society for Sports Medicine,s Specialty Day in San Diego, California ... results in terms of knee symptoms and function with both ...
... with a mechanical disorder of the hip and can be ... some cases, according to a recent study. The research, conducted ... at the American Orthopedic Society for Sports Medicine 2011 Specialty ... annual meeting of the American Academy of Orthopaedic Surgeons. ...
... Robert Reid realized he gave the same tutorial to ... Was there a way, he wondered, to transform this ... Along with medical student Bryden Magee, Dr. Reid, ... Chair of the Division of Reproductive Endocrinology and Infertility ...
... HealthDay Reporter , FRIDAY, Feb. 18 (HealthDay News) -- Months ... startled to find their artificial joint starts squeaking. Not ... one that squeaks, but those who do are likely to ... new research shows. Fortunately, the squeaks are more of ...
... , FRIDAY, Feb. 18 (HealthDay News) -- Cell ... new British study contends. An analysis of data on ... and 2007 -- when cell phone use was climbing -- ... cancers in men or women, said the University of Manchester ...
Cached Medicine News:Health News:Federal Natural Resource Trustees announce next step in BP Deepwater Horizon spill Gulf restoration 2Health News:Federal Natural Resource Trustees announce next step in BP Deepwater Horizon spill Gulf restoration 3Health News:Hamstring grafts prove more effective in ACL knee reconstruction, study says 2Health News:Common hip disorder can cause sports hernia 2Health News:Common hip disorder can cause sports hernia 3Health News:New educational DVD improves female pelvic exam instruction 2Health News:That Squeaking Sound Might Come From Your New Hip 2Health News:That Squeaking Sound Might Come From Your New Hip 3Health News:British Study Finds No Link Between Cell Phones, Brain Tumors 2
... Our breadth of infectious disease ELISA products ... With standard assay protocols for faster integration ... ELISA products provide increased reliability and run-to-run ... antibody detection assays for a wide range ...
... infectious disease ELISA products make us a ... protocols for faster integration into the busy ... increased reliability and run-to-run consistency. Our Infectious ... for a wide range of serological assays ...
... disease ELISA products make us a leader ... for faster integration into the busy laboratory, ... reliability and run-to-run consistency. Our Infectious Disease ... a wide range of serological assays including ...
Inquire...
Medicine Products: